drugset / Trial / NCT05896761
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS2M \[A2M\]) study (NCT03299049).
Timeline
- Start
- 2021-10-28
- Primary completion
- 2022-08-23
- Completion
- 2022-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | 400 mg | Intramuscular |
| Subject | Cabotegravir | Small molecule | 600 mg | Intramuscular |
| Subject | Rilpivirine | Small molecule | 600 mg | Intramuscular |
| Subject | Rilpivirine | Small molecule | 900 mg | Intramuscular |